Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age

American Journal of Obstetrics and Gynecology

Volumn 206, Issue 4, 2012, Pages 349.e1-349.e7

  Moore, Richard G ^a   Miller, Michael Craig ^a   Eklund, Elizabeth E ^b   Lu, Karen H ^c   Bast Jr , Robert C ^c   Lambert Messerlian, Geralyn ^a,b  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

biomarker; HE4; healthy women; pregnancy

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4;

AGE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL (TOPIC); HUMAN; META ANALYSIS; OVARY CANCER; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL;

EID: 84863408154     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2011.12.028     Document Type: Article

References (28)

1. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7. (Pubitemid 12235035)
2. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7. (Pubitemid 13014028)
3. Bast RC Jr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15(suppl 3):274-81. (Pubitemid 43096594)
4. Moore RG, Maclaughlan S, Bast RC Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 2009. Epub ahead of print.
5. Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919-26. (Pubitemid 46657391)
6. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
7. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC Jr. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984;64:703-7. (Pubitemid 15205480)
8. Buamah PK, Skillen AW. Serum CA 125 concentrations in patients with benign ovarian tumours. J Surg Oncol 1994;56:71-4. (Pubitemid 24209462)
9. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 2000;75:264-5.
10. Fuith LC, Daxenbichler G, Dapunt O. CA 125 in the serum and tissue of patients with gynecological disease. Arch Gynecol Obstet 1987;241:157-64. (Pubitemid 18042764)
11. Meden H, Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int J Biol Markers 1998;13:231-7. (Pubitemid 29178555)
12. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-9. (Pubitemid 40490123)
13. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700. (Pubitemid 36793054)
14. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2007;108:402-8. (Pubitemid 351174295)
15. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-9.
16. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
17. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010; 117:440-5.
18. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53. (Pubitemid 43780455)
19. Horowitz GL, Altaie S, Boyd JC, et al. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline. Clinical and Laboratory Standards Institute/International Federation of Clinical Chemisty and Laboratory Medicine 2008;28:1-76.
20. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010;31:113-9.
21. Lowe KA, Shah C, Wallace E, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2480-7.
22. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:489-93. (Pubitemid 32701635)
23. Dehaghani AS, Ghiam AF, Hosseini M, Mansouri S, Ghaderi A. Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women. Pathol Oncol Res 2007;13:360-4. (Pubitemid 351287319)
24. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21(suppl):206-10.
25. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007;44:151-78.
26. Seki K, Kikuchi Y, Uesato T, Kato K. Increased serum CA 125 levels during the first trimester of pregnancy. Acta Obstet Gynecol Scand 1986;65:583-5. (Pubitemid 17174338)
27. Fendrick JL, Staley KA, Gee MK, McDougald SR, Quirk JG Jr, O'Brien TJ. Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line. Tumour Biol 1993;14:310-8. (Pubitemid 23357720)
28. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011;118:280-8.